What question did this study set out to answer?

The research aims to examine the role of surrogate biomarkers in evaluating treatment outcomes in interventional oncology.

Survival and Surrogate Biomarkers in Interventional Oncology Trials: Pitfalls, Challenges, and Future Directions

View Full Paper

Ask AI

Bookmark

Authors

Interventional oncology evaluates surrogate endpoints in cancer care, suggesting a path for reliable outcomes.

The research aims to examine the role of surrogate biomarkers in evaluating treatment outcomes in interventional oncology.
Reviewed literature on the use of surrogate endpoints in interventional oncology trials.
Evaluated regulatory and methodological challenges in the field.
Analyzed specific cases, including hepatocellular carcinoma and metastatic liver diseases.
Variable predictive strength of surrogate endpoints noted across different studies.
Regulatory acceptance and validation of endpoints remain inconsistent.
Integration of advanced methodologies is recommended to enhance surrogate endpoint reliability.

Sampol et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark